In partnership with GS2, the U.S. Department of Veterans Affairs (VA) has awarded a contract to Linear Health Sciences for its Orchid SRV tension-activated breakaway safety release valve.

美国退伍军人事务部（VA）与GS2合作，将兰花SRV张力激活分离安全释放阀的合同授予线性健康科学公司。

The Orchid SRV is a sterile, single-use connector for needle-free access that makes return to treatment fast, simple, and clean, according to the company. Clinical simulation testing of 360 Orchid SRVs showed the device prevented IV dislodgement by 91.9% across all test groups. The device is placed between an existing IV extension set and general IV tubing connection that delivers fluids to and from an IV catheter.

据该公司介绍，Orchid SRV是一种无菌一次性连接器，用于无针进入，可以快速，简单且干净地恢复治疗。360个Orchid SRV的临床模拟测试表明，该装置在所有测试组中可防止静脉移位91.9%。该装置放置在现有的IV延长装置和一般IV管连接之间，该连接将流体输送到IV导管和从IV导管输送流体。

“This contract allows the VA system to evaluate and adopt the Orchid SRV in a patient population that can directly benefit from its function,” Linear Health Sciences Co-Founder/CEO Dan Clark said. “It’s a significant step toward providing our veterans with the level of care they deserve.”

Linear Health Sciences联合创始人/首席执行官丹·克拉克（DanClark）表示：“该合同允许VA系统评估并采用兰花SRV，使患者群体能够直接受益。”。“这是向我们的退伍军人提供他们应得的护理水平迈出的重要一步。”

According to a study published in J-AVA, 95% of 1,561 U.S. clinicians surveyed agreed that IV dislodgement continues to pose safety risks for patients and hospitals. Of the 342 million peripheral IVs deployed each year in the U.S.,1 up to 10% may dislodge,2 costing more than $2 billion annually.3 Dislodgement is most frequently caused by patient confusion or removal of the catheter, loose dressing or tape, or tubing becoming tangled in bed linens.

根据J-AVA上发表的一项研究，在接受调查的1561名美国临床医生中，95%的人同意静脉移位继续对患者和医院构成安全风险。在美国每年部署的3.42亿个外围IVs中，1%至10%可能会移位，2%每年花费超过20亿美元。3移位最常见的原因是患者混淆或导管移除，敷料或胶带松动，或管道在床单上缠结。

“This device is innovative, saves hospitals money, and increases customer service and quality of care for all patients who need an IV. Veterans deserve the best technology offered on the market today. The Orchid should be in stock at every VA hospital,” GS2 Global CEO Blaine Hedges stated.

GS2全球首席执行官布莱恩·赫奇斯（BlaineHedges）表示：“这种设备具有创新性，为医院节省了资金，并为所有需要静脉注射的患者提高了客户服务和护理质量。退伍军人应该拥有当今市场上提供的最佳技术。弗吉尼亚州每家医院都应该有兰花库存。”。

The Orchid SRV has also received an Innovative Technology contract from Vizient Inc., the nation’s largest member-driven healthcare performance improvement company, and was awarded a national group purchasing agreement for the IV Therapy - Needleless Connectors category with Premier Inc.

兰花SRV还获得了Vizient Inc.的创新技术合同，Vizient Inc.是美国最大的会员驱动型医疗保健绩效改进公司，并获得了与Premier Inc.签订的IV疗法-无针连接器类别的国家集团采购协议。

Linear Health Sciences has developed a proprietary, breakaway safety valve technology designed to improve hospitals' medical tubing use. The platform technology was developed to increase the safety and satisfaction of patients, caregivers, and healthcare facilities, while dramatically reducing costs.

Linear Health Sciences开发了一种专有的分离式安全阀技术，旨在改善医院的医疗管道使用。开发平台技术是为了提高患者、护理人员和医疗机构的安全性和满意度，同时大大降低成本。

The company’s initial products include the Orchid SRV for use in IV catheter therapy and the Orchid SRV Type D device for use in surgical/wound, nephrostomy and abscess drainage. .

该公司的初始产品包括用于静脉导管治疗的兰花SRV和用于手术/伤口，肾造口术和脓肿引流的兰花SRV D型装置。